State Medicaid program; modifying appointment procedures for the Medicaid Drug Utilization Review Board. Effective date.
SB 927 amends Oklahoma's Medicaid Drug Utilization Review Board procedures by prohibiting the pharmaceutical industry representative from voting on drug-related matters. It updates the appointment process to stagger initial terms for one physician, one pharmacist, and the lay representative to ensure board continuity. The bill affects the Oklahoma Health Care Authority and the board members, with changes taking effect November 1, 2025. The board's composition (10 members: 4 physicians, 4 pharmacists, 1 lay representative, 1 pharmaceutical industry rep) and appointment lists remain unchanged.
Bill status
vetoed
4 of 5 stages cleared
Introduction
Feb 2025
Committee Review
May 2025
Senate Passage
Mar 2025
House Passage
May 2025
Vetoed
May 2025
Introduced Feb 3, 2025
Vetoed May 14, 2025
Maddy AI version diff · 4 comparisons
What changed between versions
Floor (House)
→
Floor (Senate)
·
6 edits
MODERATE
The bill was moved from the House version to the Senate floor version, with substantive changes to the composition and appointment rules for the Medicaid Drug Utilization Review Board. The Senate version adds specific requirements for industry representation and voting restrictions, while also clarifying term lengths and staggered appointment procedures.
Scope change
The bill's scope remains focused on the Medicaid Drug Utilization Review Board, but the Senate version introduces more detailed requirements for board member selection and voting restrictions for industry representatives.
REQUIREMENT
Added specific voting restrictions for the pharmaceutical industry representative who cannot vote on drug-related items
Changed physician appointment requirements to specify three physicians from OSMAS and one from OOA
Clarified that the lay community representative must be a healthcare professional with specific expertise in drug use review or quality assurance
Added requirement for pharmaceutical industry representative from Pharmaceutical Research and Manufacturers of America
Added geographic balance requirement when making appointments to the board
TIMELINE
Changed effective date from unspecified to November 1, 2025
Floor votes · Senate Mar 17, 2025 · House May 7, 2025
How they voted
46–0
Passed · 3 other
Total votes 49
Mar 17, 2025
D
Democratic9
100% Yea
R
Republican40
92% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
24
Key actions
6
Committee
6
May 14, 2025
Vetoed
Vetoed 05/14/2025
upper
May 7, 2025
Committee
Referred for enrollment
upper
May 7, 2025
Lower · Passed
Third Reading, Measure passed: Ayes: 56 Nays: 31
lower
Apr 16, 2025
Lower · Passed
CR; Do Pass Health and Human Services Oversight Committee
lower
Apr 9, 2025
Lower · Passed
Policy recommendation to the Health and Human Services Oversight committee; Do Pass Public Health
lower
Apr 1, 2025
Committee
Referred to Public Health
lower
Mar 18, 2025
Introduced
First Reading
lower
Mar 18, 2025
Upper · Passed
Engrossed to House
upper
Mar 17, 2025
Committee
Referred for engrossment
upper
Mar 17, 2025
Upper · Passed
Measure passed: Ayes: 44 Nays: 0
upper
Feb 24, 2025
Upper · Passed
Reported Do Pass Health and Human Services committee; CR filed
upper
Feb 3, 2025
Introduced
First Reading
upper
2 primary · 0 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 927
Scope: OK
Hi! I can help you understand SB 927. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline